Written and maintained by CASRAI Editorial Board
Last updated
Short answer: Carbon ion therapy (carbon ion radiotherapy, CIRT) is external-beam radiation delivered with carbon nuclei instead of photons or protons. Carbon ions deposit most of their energy in a sharp peak near the end of their path and are biologically more effective per unit of dose than photons, so planning must account for both dose and relative biological effectiveness (RBE). Clinical evidence is mostly non-randomized.
This page is general educational information for researchers and clinic or lab staff. It is not medical advice and does not describe treatment procedures.
Definition and scope
Carbon ion therapy is a form of particle (hadron) radiotherapy. A particle accelerator brings carbon ions to high speed and directs them at a target volume. It sits alongside proton therapy within particle therapy; for the wider field, see what radiation oncology is and how its research is organised, and nuclear physics for the underlying science.
How carbon ion therapy works
Two properties distinguish heavy-ion beams: where the dose lands (physics) and how damaging that dose is (biology). The chain below summarises the points reported in two open-access reviews (sources 1 and 2).
| Step | What the reviews report |
|---|---|
| Bragg peak | Energy is deposited abruptly at the end of the particle track, and the dose falls off dramatically beyond it (Mohamad et al. 2017). Carbon beams show a sharper lateral penumbra than other beams (Lazar et al. 2018). |
| Fragmentation tail | Some carbon nuclei break into lighter fragments that travel past the peak, producing a low-dose, low-LET tail beyond it (Mohamad et al. 2017). |
| Linear energy transfer (LET) | LET is determined primarily by a particle’s charge and speed. It rises as the particle slows, so the high-LET portion of the track lies in the tumour region (Mohamad et al. 2017). |
| RBE | Carbon-ion RBE is at least two- to three-fold that of photons depending on volume, while proton RBE is only slightly above 1 (Lazar et al. 2018). Clinical carbon RBE is generally estimated at 2.5 to 3, with values up to 5 reported, peaking at the distal edge of the Bragg peak (Mohamad et al. 2017). |
| Oxygen enhancement ratio (OER) | OER is about 3 for low-LET photons and protons; for carbon and heavier ions it varies with LET and charge, from 2.5 down to 1.0 (Mohamad et al. 2017). |
Because oxygen-poor (hypoxic) tumour cells resist photons, a lower OER is the basis for the hypothesis that hypoxia-related resistance may be overcome with carbon ions (Lazar et al. 2018). That is stated in the review as a hypothesis, not an established clinical result.
Carbon ions compared with protons and photons
Only the rows below are supported by the sources read.
| Property | Photons | Protons | Carbon ions |
|---|---|---|---|
| RBE relative to photons | Reference | Only slightly higher than unity | At least 2 to 3 times, depending on volume |
| OER | About 3 (low LET) | About 3 (low LET) | 2.5 down to 1.0, varying with LET and charge |
| Lateral penumbra | Reported as sharper for carbon than for other beams | Sharper | |
Why RBE variability matters
Lazar et al. report considerable variability in the RBE of CIRT across biological models and planning approaches. For research staff, this means dose numbers from different centres are not automatically comparable: check which RBE model a trial or paper used before pooling or comparing results.
Evidence and facilities
In their review of registered trials, Lazar et al. found that of 63 CIRT trials, 84% were non-randomized, 10 were randomized and 3 (5%) were phase III; none used overall survival as the primary endpoint. They state that high-level phase III randomized evidence does not exist. Tumour types discussed include rare tumours such as skull-base sarcomas; prostate was the most treated site in Japan.
When appraising CIRT studies, the same questions apply as for any trial: see randomized controlled trial, clinical trial protocol and clinical trial registration.
Facility counts are snapshots. Lazar et al. (2018) reported 11 CIRT facilities worldwide and roughly 20,000 patients treated, drawing on the Particle Therapy Co-Operative Group (PTCOG) database. Mohamad et al. (2017) reported 10 centres treating with carbon ions, with clinical data mostly from Japan and Germany and no heavy-ion facility in North America at that time. The PTCOG site is the primary source for current counts.
Common misunderstandings
- “A higher RBE means a stronger dose number.” RBE converts physical dose to biological effect; it is not constant and varies with LET, depth, tissue and model.
- “The dose stops at the Bragg peak.” Fragmentation produces a low-dose tail beyond the peak.
- “Carbon ion therapy is proven superior.” The reviewed trial base is mostly non-randomized, with no phase III evidence on overall survival as a primary endpoint.
- “Carbon ions and protons behave alike.” Their RBE and OER differ, per the table above.
FAQ
What is carbon ion therapy?
It is radiotherapy delivered with accelerated carbon nuclei, which concentrate dose near the end of their range and have a higher RBE than photons or protons.
How is it different from proton therapy?
Both use a Bragg peak. Carbon ions have a markedly higher RBE (2.5 to 3 clinically versus slightly above 1 for protons) and a different OER, and produce a fragmentation tail beyond the peak.
How strong is the clinical evidence?
Mostly non-randomized: 84% of 63 reviewed trials, with 3 phase III and none using overall survival as the primary endpoint (Lazar et al. 2018).
Sources
- Lazar AA, Schulte R, Faddegon B, Blakely EA, Roach M III. Clinical Trials Involving Carbon Ion Radiation Therapy and the Path Forward. Cancer 2018;124(23):4467-4476. pmc.ncbi.nlm.nih.gov/articles/PMC6540799 (read 2026-11-11).
- Mohamad O et al. Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers (Basel) 2017;9(6):66. doi:10.3390/cancers9060066. pmc.ncbi.nlm.nih.gov/articles/PMC5483885 (read 2026-11-11).
